Library Subscription: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Published 4 issues per year

ISSN Print: 0731-8898

ISSN Online: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Recent Evidence and Possible Therapy against COVID-19-Mediated Hepatic Dysfunction

Volume 40, Issue 4, 2021, pp. 33-41
DOI: 10.1615/JEnvironPatholToxicolOncol.2021039357
Get accessGet access

ABSTRACT

Over the years, a novel RNA coronavirus has emerged with mutational episodes. This virus was confirmed to cause severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus infectious disease-2019 (COVID-19). This particular emphasis has raised the risk signal at the global level. Hepatic injury has been known to be a major impairment with varying factors. In recent years, the mechanistic event of hepatic injury is now more controversial and has a lack of justifiable set. Nevertheless, it has been investigated for the prominence of inflammatory signals, viral load in hepatocytes, followed by an intensive care therapeutic defense, and/or drug toxicity. Limited reports are available on infection-mediated hepatic injury, and its associated mechanism is still poorly understood. In the context of COVID-19 infections, the initial episode is pulmonary disorder with a systemic infection in multiple organs, including the liver. The majority of the reported cases reveal hepatic damage or dysfunction among COVID-19-infected patients. Prevalence of altered biochemistry of liver enzymes was also observed in the COVID-19 infected population. Our review focuses on the probable mechanisms and therapeutic options of COVID-19 and its associated hepatic dysfunction. We also discuss the available prescribed medications against COVID-19 infections, such as remdesiver, oseltamivir, lopina-vir/ritonavir, ribavirin, anticoagulant, anti-inflammatory, and immune-based therapies.

REFERENCES
  1. Yesudhas D, Srivastava A, Gromiha MM. COVID-19 out-break: History, mechanism, transmission, structural studies and therapeutics. Infection. 2021;49(2):199-213.

  2. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3): 141-54.

  3. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552-5.

  4. Perrotta F, Matera MG, Cazzola M, Bianco A. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? Respir Med. 2020;168:105996.

  5. Baig AM. Computing the effects of SARS-CoV-2 on respiration regulatory mechanisms in COVID-19. ACS Chem Neurosci. 2020;11(16):2416-21.

  6. Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66-70.

  7. White MA, Lin W, Cheng X. Discovery of COVID-19 inhibitors targeting the SARS-CoV2 Nsp13 helicase. Phys Chem Lett. 2020;11(21):9144-51.

  8. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368:m1091.

  9. Ponziani FR, Del Zompo F, Nesci A, Santopaolo F, Ianiro G, Gasbarrini A, Pompili M; Gemelli against COVID-19 group. Letter: Liver involvement and mortality in COVID-19 patients - Authors' reply. Aliment Pharmacol Ther. 2020;52(7):1264-5.

  10. Bertolini A, van de Peppel IP, Bodewes F, Moshage H, Fantin A, Farinati F, Fiorotto R, Jonker JW, Strazzabosco M, Verkade HJ, Peserico G. Abnormal liver function tests in patients With COVID-19: Relevance and potential pathogenesis. Hepatology. 2020;72(5):1864-72.

  11. Liao FL, Peng DH, Chen W, Hu HN, Tang P, Liu YY, Luo Y, Yao T. Evaluation of serum hepatic enzyme activities in different COVID-19 phenotypes. J Med Virol. 2021;93(4):2365-73.

  12. Effenberger M, Grander C, Grabherr F, Griesmacher A, Ploner T, Hartig F, Bellmann-Weiler R, Joannidis M, Zoller H, Weiss G, Adolph TE, Tilg H. Systemic inflammation as fuel for acute liver injury in COVID-19. Dig Liver Dis. 2021;53(2):158-65.

  13. Ali N, Hossain K. Liver injury in severe COVID-19 infec-tion: Current insights and challenges. Expert Rev Gastro-enterol Hepatol. 2020;14(10):879-84.

  14. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, Jiang Y, Cheng X, Zhu C, Xia Y. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123-30.

  15. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-47.

  16. Higuera-de la Tijera F, Servin-Caamano A, Reyes-Herrera D, Flores-Lopez A, Robiou-Vivero EJA, Martinez-Rivera F, Galindo-Hernandez V, Chapa-Azuela O, Chavez-Morales A, Rosales-Salyano VH. Impact of liver enzymes on SARS-CoV-2 infection and the severity of clinical course of COVID-19. Liver Res. 2021;5(1):21-7.

  17. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): A clinical update. Front Med. 2020;14(2): 126-35.

  18. Choudhary J, Dheeman S, Sharma V, Katiyar P, Karn SK, Sarangi MK, Chauhan AK, Verma G, Baliyan N. Insights of severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic: A current review. Biol Proced Online. 2021;23(1):5.

  19. Albini A, Di Guardo G, Noonan DM, Lombardo M. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: Implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Intern Emerg Med. 2020;15(5):759-66.

  20. Salamanna F, Maglio M, Landini MP, Fini M. Body localization of ACE-2: On the trail of the keyhole of SARS-CoV-2. Front Med. 2020;7:594495.

  21. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73(4):807-16.

  22. Aleksova A, Gagno G, Sinagra G, Beltrami AP, Janjusevic M, Ippolito G, Zumla A, Fluca AL, Ferro F. Effects of SARS-CoV-2 on cardiovascular system: The dual role of angiotensin-converting enzyme 2 (ACE2) as the virus receptor and homeostasis regulator. Int J Mol Sci. 2021;22(9):4526.

  23. Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020;10:317.

  24. Singh V, Beer A, Kraus A, Mang F, Zhang X, Xue J, Hagemann N, Hermann DM, Gunzer M. Stroke increases the expression of ACE2, the SARS-CoV-2 binding receptor, in murine lungs. Brain Behav Immun. 2021;94:458-62.

  25. Habashi NM, Camporota L, Gatto LA, Nieman G. Functional pathophysiology of SARS-CoV-2-induced acute lung injury and clinical implications. J Appl Physiol. 2021;130(3):877-91.

  26. Miller SE. Visualization of SARS-CoV-2 in the lung. N Engl J Med. 2020;383(27):2689.

  27. Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, Chen G, Wang K, Yu J, Wu Z, Chen X, Wang G. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomed Pharmacother. 2021;133:110825.

  28. Guan GW, Gao L, Wang JW, Wen XJ, Mao TH, Peng SW, Zhang T, Chen XM, Lu FM. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia. Zhonghua Gan Zang Bing Za Zhi. 2020;28(2):100-06 (in Chinese).

  29. Zou X, Fang M, Li S, Wu L, Gao B, Gao H, Ran X, Bian Y, Li R, ShanshanYu, Ling J, Li D, Tian D, Huang J. Characteristics of liver function in patients with SARS-CoV-2 and chronic HBV coinfection. Clin Gastroenterol Hepatol. 2021;19(3):597-603.

  30. Shao T, Tong Y, Lu S, Jeyarajan AJ, Su F, Dai J, Shi J, Huang J, Hu C, Wu L, Dai X, Cheng Z, Yan J, Huang P, Tian Y, Li S, Chung RT, Chen D. y-Glutamyltransferase elevations are frequent in patients with COVID-19: A clinical epidemiologic study. Hepatol Commun. 2020;4(12):1744-50.

  31. Huang C, Li Q, Xu W, Chen L. Molecular and cellular mechanisms of liver dysfunction in COVID-19. Discov Med. 2020;30(160):107-12.

  32. Cheong J, Bartell N, Peeraphatdit T, Mosli M, Al-Judaibi B. Gastrointestinal and liver manifestations of COVID-19. Saudi J Gastroenterol. 2020;26(5):226-32.

  33. Dao TL, Hoang VT, Gautret P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: A narrative review. Eur J Clin Microbiol Infect Dis. 2021;40(1):13-25.

  34. Lagana SM, Kudose S, Iuga AC, Lee MJ, Fazlollahi L, Remotti HE, Del Portillo A, De Michele S, de Gonzalez AK, Saqi A, Khairallah P, Chong AM, Park H, Uhlemann AC, Lefkowitch JH, Verna EC. Hepatic pathology in patients dying of COVID-19: A series of 40 cases including clinical, histologic, and virologic data. Mod Pathol. 2020;33(11):2147-55.

  35. Shenoy S. Coronavirus (COVID-19) sepsis: Revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality. Inflamm Res. 2020;69(11):1077-85.

  36. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodriguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62-75.

  37. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, Su Y, Ma Z, Zhang Y, Li Z, He Q, Liu L, Fu Y, Chen J. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75(7):1742-52.

  38. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, Terlecki G, Gamian A. Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med. 2008;46(3):359-64.

  39. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452.

  40. Maggi U, De Carlis L, Yiu D, Colledan M, Regalia E, Rossi G, Angrisani M, Consonni D, Fornoni G, Piccolo G, DeFeo TM. The impact of the COVID-19 outbreak on liver transplantation programs in Northern Italy. Am J Transplant. 2020;20(7):1840-8.

  41. Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020;73(5):1231-40.

  42. Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020;2(5):100169.

  43. Reuken PA, Rauchfuss F, Albers S, Settmacher U, Trautwein C, Brans T, Stallmach A. Between fear and courage: Attitudes, beliefs, and behavior of liver transplantation recipients and waiting list candidates during the COVID-19 pandemic. Am J Transplant. 2020;20(11):3042-50.

  44. Uzunova K, Filipova E, Pavlova V, Vekov T. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother. 2020;131:110668.

  45. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int. 2020;40(9):2095-103.

  46. Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. 2020;40(6):1278-81.

  47. Liu Q, Wang RS, Qu GQ, Wang YY, Liu P, Zhu YZ, Fei G, Ren L, Zhou YW, Liu L. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi. 2020;36(1):21-3 (in Chinese).

  48. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, Wei S, Deng Y, Liu J, Liu H-G, Yang M, Hu Y. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020;133(9):1032-8.

  49. Zhao B, Ni C, Gao R, Wang Y, Yang L, Wei J, Lv T, Liang J, Zhang Q, Xu W, Xie Y, Wang X, Yuan Z, Liang J, Zhang R, Lin X. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020;11(10):771-5.

  50. Cabibbo G, Rizzo GEM, Stornello C, Craxi A. SARS-CoV-2 infection in patients with a normal or abnormal liver. J Viral Hepat. 2021;28(1):4-11.

  51. Farshidpour M, Kim D, Junna S, Merchant J. A brief review of liver injury in patients with Corona Virus Disease-19 during the pandemic. Indian J Gastroenterol. 2020;39(3):232-5.

  52. Wei LL, Wang WJ, Chen DX, Xu B. Dysregulation of the immune response affects the outcome of critical COVID-19 patients. J Med Virol. 2020;92(11):2768-76.

  53. Dong V, Nanchal R, Karvellas CJ. Pathophysiology of acute liver failure. Nutr Clin Pract. 2020;35(1):24-9.

  54. Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020;2(5):100169.

  55. Yang RX, Zheng RD, Fan JG. Etiology and management of liver injury in patients with COVID-19. World J Gastroenterol. 2020;26(32):4753-62.

  56. Zhang LX, Lv Y, Xu AM, Wang HZ. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer. 2019;19(1):841.

  57. Yang N, Shen HM. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. Int J Biol Sci. 2020;16(10):1724-31.

  58. Yao Y, Lawrence DA. Susceptibility to COVID-19 in populations with health disparities: Posited involvement of mitochondrial disorder, socioeconomic stress, and pollutants. J Biochem Mol Toxicol. 2021;35(1): e22626.

  59. Lenti MV, Borrelli de Andreis F, Pellegrino I, Klersy C, Merli S, Miceli E, Aronico N, Mengoli C, Di Stefano M, Cococcia S, Santacroce G, Soriano S, Melazzini F, Delliponti M, Baldanti F, Triarico A, Corazza GR, Pinzani M, Di Sabatino A; Internal Medicine COVID-19 Team. Impact of COVID-19 on liver function: Results from an internal medicine unit in Northern Italy. Intern Emerg Med. 2020;15(8):1399-407.

  60. Kreivenaite E, Gedgaudas R, Valantiene I, Mickiene A, Kupcinskas J. COVID-19 in a patient with liver cirrhosis. J Gastrointestin Liver Dis. 2020;29(2):263-6.

  61. Alsharif W, Qurashi A. Effectiveness of COVID-19 di-agnosis and management tools: A review. Radiography. 2021;27(2):682-7.

  62. Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): Diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci. 2020;24(7):4016-26.

  63. Pawlak KM, Kral J, Khan R, Amin S, Bilal M, Lui RN, Sandhu DS, Hashim A, Bollipo S, Charabaty A, de-Madaria E, Rodriguez-Parra AF, Sanchez-Luna SA, Zorniak M, Walsh CM, Grover SC, Siau K. Impact of COVID-19 on endoscopy trainees: An international survey. Gastrointest Endosc. 2020;92(4):925-35.

  64. Soetikno R, Teoh AYB, Kaltenbach T, Lau JYW, Asokkumar R, Cabral-Prodigalidad P, Shergill A. Considerations in performing endoscopy during the COVID-19 pandemic. Gastrointest Endosc. 2020;92(1):176-83.

  65. Musa S. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now? Arab J Gastroenterol. 2020;21(1):3-8.

  66. Iavarone M, Sangiovanni A, Carrafiello G, Rossi G, Lampertico P. Management of hepatocellular carcinoma in the time of COVID-19. Ann Oncol. 2020;31(8): 1084-5.

  67. Mehta N, Parikh N, Kelley RK, Hameed B, Singal AG. Surveillance and monitoring of hepatocellular carcinoma during the COVID-19 pandemic. Clin Gastroenterol Hepatol. 2021;19(8):1520-30.

  68. Falasca L, Nardacci R, Colombo D, Lalle E, Di Caro A, Nicastri E, Antinori A, Petrosillo N, Marchioni L, Biava G, D'Offizi G, Palmieri F, Goletti D, Zumla A, Ippolito G, Piacentini M, Del Nonno F. Postmortem findings in Italian patients with COVID-19: A descriptive full autopsy study of cases with and without comorbidities. J Infect Dis. 2020;222(11):1807-15.

  69. Conti P, Caraffa A, Gallenga CE, Ross R, Kritas SK, Frydas I, Younes A, Ronconi G. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: A promising inhibitory strategy. J Biol Regul Homeost Agents. 2020;34(6):1971-5.

  70. Ji D, Zhang D, Yang T, Mu J, Zhao P, Xu J, Li C, Cheng G, Wang Y, Chen Z, Qin E, Lau G. Effect of COVID-19 on patients with compensated chronic liver diseases. Hepatol Int. 2020;14(5):701-10.

  71. Shannon A, Le NT, Selisko B, Eydoux C, Alvarez K, Guillemot JC, Decroly E, Peersen O, Ferron F, Canard B. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites. Antiviral Res. 2020;178:104793.

  72. Malin JJ, Suarez I, Priesner V, Fatkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev. 2020;34(1):e00162-20.

  73. Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res. 2015;21(6):1248-57.

  74. Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, Torre A, Cossu MV, Minari C, Ballone E, Perotti A, Mileto D, Niero F, Merli S, Foschi A, Vimercati S, Rizzardini G, Sollima S, Bradanini L, Galimberti L, Colombo R, Micheli V, Negri C, Ridolfo AL, Meroni L, Galli M, Antinori S, Corbellino M. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36-42.

CITED BY
  1. Liu Qi, Chi Sensen, Dmytruk Kostyantyn, Dmytruk Olena, Tan Shuai, Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19, Viruses, 14, 7, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain